Nisman, B <br/><br/>
Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?  [electronic resource] 

 -  Cancer  May 1998 
 - 1850-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Controlled Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0008-543X 
<br/><br/><label>Standard No.: </label>10.1002/(sici)1097-0142(19980515)82:10<1850::aid-cncr6>3.0.co;2-r  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antigens, Neoplasm--analysis<br/>Biomarkers, Tumor<br/>Carcinoembryonic Antigen--analysis<br/>Carcinoma, Non-Small-Cell Lung--immunology<br/>Evaluation Studies as Topic<br/>Female<br/>Humans<br/>Keratin-19<br/>Keratins--analysis<br/>Lung Neoplasms--immunology<br/>Male<br/>Middle Aged<br/>Monitoring, Physiologic--methods<br/>Neoplasm Staging<br/>Peptides--analysis<br/>Predictive Value of Tests<br/>Prognosis<br/>Prospective Studies